Pangobatan kanker ati, ubar sasaran kanker ati, kombinasi anyar obat kanker ati sacara signifikan manjangkeun kasalametan.
Kangker & tingkat salamet
The number of people that survive for five years after being diagnosed with digestive system cancers seems to be particularly low in India compared to more advanced countries. Survival rates are just 19% for stomach cancer compared to 25-30% in most countries, with 58% surviving in South Korea. In India, the survival rate for kanker titik is 37% while it is 50-59% in most countries and goes up to 65% in the US. Only 4% of kanker haté patients survive for five years in India compared to 10 to 20% elsewhere. Survival rates have dipped in the case of rectal cancer in India.
Even in breast and kanker prostat, where medical advances have ensured that over 80% of patients survive in advanced countries, only about 60% of Indian patients survive. kanker indung survival rates have declined in India from 23% in 1995-99 to 14% in 2005-09. kanker cervical survival rates are 46% compared to the global figure of 50%, but there is a slight decline in India from 47% in 2005. It is understood that there are one million new liver cancer patients worldwide each year, of which 55% are patients in China. About 110,000 people die of liver cancer each year in China, and the 5-year recurrence rate in China is as high as 70%. Liver cancer is highly malignant and highly contagious.
Gejala mimiti kanker ati
1. Cough: The liver mass stimulates the diaphragm. During breathing, it causes a reflex in the lungs to cause a cough, or liver cancer has lung metastases that cause a cough.
2. Kacapean: Sél kanker ngarusak fungsi panyimpenan ati sareng suplai énergi awak dikirangan.
3. Ngirangan beurat awak anu teu tiasa dijelaskeun: Sél kanker peryogi langkung énergi sareng nutrisi tibatan jaringan normal nalika prosés tumuh, nyababkeun kurangna nutrisi dina awak, janten pasién nunjukkeun nambahan beurat. Kanker anu sanés ogé nunjukkeun tanda-tanda pembuangan.
4. Gejala gastrointestinal: gangguan pencernaan lumangsung. Sakitar sapertilu pasién kanker haté bakal ngalaman gejala panyakit saluran pencernaan dina tahap awal panyakit, sami sareng panyakit lambung.
5. Fever: mostly cancerous fever, which is mainly caused by the release of pyrogens into human blood circulation after tumor nekrosis jaringan.
6. Pendarahan: permén karét, perdarahan subkutan, sareng gejala anu sanés.
7. Nyeri: Nyeri hépatik lumangsung dina kalolobaan penderita kanker liver maju.
Naha seueur penderita kanker ati di nagara berkembang? Naon sababna kanker hati?
1. Alkoholisme sareng hépatitis alkohol: Alkohol sareng métabolit beracun asetaldehida tiasa nyababkeun ati lemak alkohol, hépatitis alkohol, bahkan fibrosis ati sareng kanker ati.
2. Obesitas jeung lemak ati: Obesitas mangrupakeun salah sahiji akar ngabalukarkeun loba panyakit kronis. Obesitas bisa ngabalukarkeun masalah ati lemak komo worsen kana sirosis jeung kanker ati. Biasana, perhatoskeun 7 poin anu pinuh ku diet, kabiasaan olahraga anu saé, tuang tuangeun lemak tinggi sareng gaya hirup tuangeun gula anu luhur.
3. B / C hépatitis viral: hépatitis B kronis sareng C mangrupikeun panyabab utama kanker ati baheula, kira-kira 60 ~ 70%. Kalayan palaksanaan pinuh ku vaksin hépatitis B pikeun bayi anu énggal, proporsi inféksi hépatitis B parantos turun. Hépatitis C ogé pohara populér sababaraha taun ka tukang. Hépatitis C ayeuna tiasa diubaran sareng ancaman hépatitis virus ngirangan.
Kumaha carana nyegah kanker ati tina teu ngulang deui?
1. Perawatan konsolidasi aktip. Bedah sareng pangobatan anu aya hubunganana tiasa ngaleungitkeun seueur jaringan tumor, tapi sél kanker teu tiasa dipiceun lengkep. Sél kanker résidu gaduh kamungkinan luhur deui; ku alatan éta, perlakuan konsolidasi kudu dilaksanakeun dina waktu anu tepat. Pangobatan tradisional Cina sareng ubar pikeun panangtayungan ati sareng ati tiasa dianggo kanggo waktos anu lami.
2. Aktip latihan pikeun nguatkeun imunitas anjeun sareng tahan kana panyakit.
3. Diét anu saimbang, nguatkeun nutrisi, ngirangan asupan gajih sareng ngirangan nyerep zat toksik.
4. Ngajaga méntalitas anu saé, biasana diajar nyaluyukeun méntalitas sareng émosina, ngahontal kombinasi padamelan sareng istirahat, sareng ngajauhan padamelan teuing. Setrés sareng kacapean tiasa nyababkeun lemah awak, anu tiasa nyababkeun imunitas rendah sareng imunitas rendah, anu tiasa nyababkeun kanker.
Kumaha cara ngubaran kanker hati sareng naon ubar énggal?
Liver cancer treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
Obat anu ditujukeun kanker haté
| ngaran umum | Ngaran Produk | tujuan | Waktu keur pasar | Cina didaptarkeun | Panaliti aslina | Jenis ubar |
| Sorafenib | Nexavar, Dogemei | KIT, VEGFR, PDGFR | 2005 | nuhun | bayer | Molekul leutik |
| Regorafenib | Stivarga | Multi-udagan | 2012 | No | bayer | Molekul leutik |
| Ramucirumab | Cyramza | VEGFR2 | 2014 | nuhun | Eli Lilly | MAb |
| Lenvatinib | Lenvima | Multi-udagan | 2015 | nuhun | Ésai | Molekul leutik |
Kombinasi atejizumab sareng bevacizumab langkung saé tibatan monoterapi
Recently, the European Society of Oncology 2019 (Asian Congress) held in Singapore announced the phase III of the tumor immunotherapy Tecentriq (atezolizumab, atuzumab) combined with Avastin (bevacizumab) first-line treatment of hepatocellular carcinoma (HCC). Clinical study IMbrave150 (NCT03434379). Compared to sorafenib, the first-line combination of atrezumab and bevacizumab has statistically and clinically improved progression-free survival (PFS) and overall survival (OS). The risk of death was reduced by 42% in patients receiving combination therapy, and the progression-free survival rate was 41% (no progression or risk of death).
In addition, in December 2018, the US FDA approved atezolizumab combined with bevacizumab + chemotherapy (carboplatin and paclitaxel) as first-line treatment for adult patients with metastatic non-squamous kanker paru sél non-leutik without EGFR or ALK genome tumor aberrations. Based on data from group B of the IMpower150 study, compared with bevacizumab + chemotherapy, atezolizumab combined with bevacizumab + chemotherapy significantly prolonged patient survival (19.2 months vs 14.7 months).
Atuzumab mangrupikeun antibodi PD-L1 sareng milik immunotherapy tumor. Ubar kasebut tiasa ngabeungkeut protéin anu disebut PD-L1 anu dinyatakeun dina sél tumor sareng sél imun anu nyusup tumor, ngahalangan tina PD-1 sareng B7. .1 interaksi reséptor. Ku ngahambat PD-1, atuzumab tiasa ngaktifkeun sél T, anu berpotensi dianggo salaku terapi kombinasi dasar pikeun imunoterapi kanker, ubar anu dituju sareng sagala rupa kémoterapi kanker.
Bevacizumab mangrupikeun panghambat angiogenesis anu nargétkeun ngariung sareng faktor pertumbuhan endothelial vaskular (VEGF). VEGF maénkeun peran penting dina angiogenesis sareng perawatan dina siklus kahirupan tumor. Avastin nginféksi suplai getih tina tumor ku cara ngariung langsung ka VEGF, nyegah tina berinteraksi sareng reséptor dina sél vaskular. Suplai getih tina tumor dianggap
konci pikeun kamampuanna pikeun numuh sareng metastasize dina vivo.
Aya dasar ilmiah anu kuat pikeun ngagabungkeun atelizumab sareng bevacizumab, sareng gabungan tina dua ubar ngagaduhan poténsial pikeun nguatkeun sistim imun ngalawan tumor. Salaku tambahan kana pangaruh anti-angiogenik na, bevacizumab tiasa langkung ningkatkeun atezumab pikeun malikkeun résistansi awak ku cara ngahambat imunosupresi anu aya hubunganana sareng VEGF, ngamajukeun resapan tumor-sél T, sareng ngamimitian réspon sél T kana antigén tumor. Kekebalan kanker.
